ArticleThe oncologist2018
Revisiting Expectations in an Era of Precision Oncology.
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework.JCO precision oncology · 2025Pooled it
- Precision cancer medicine and the doctor-patient relationship: a systematic review and narrative synthesis.BMC medical informatics and decision making · 2023Pooled it
- Trial
- Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: A scoping review.Cancer medicine · 2024Article
- Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences.BMJ open · 2023Article
- Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing.JCO precision oncology · 2023Article
- A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests.Current oncology (Toronto, Ont.) · 2022Article
- A sociology of precision-in-practice: The affective and temporal complexities of everyday clinical care.Sociology of health & illness · 2021Article
- Predicting chemotherapy response using a variational autoencoder approach.BMC bioinformatics · 2021Article
- Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Ethical considerations in neurology during the COVID-19 pandemic.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices.JCO precision oncology · 2021Article
- "My Research Is Their Business, but I'm Not Their Business": Patient and Clinician Perspectives on Commercialization of Precision Oncology Data.The oncologist · 2020Article
- Cancer Research Ethics and COVID-19.The oncologist · 2020Article
- Dissemination and Implementation of Palliative Care in Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- Navigating the Informed Consent Process When Using Innovative Surgery.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2020Review
- Patient and Provider Perspectives Regarding Enrollment in Head and Neck Cancer Research.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2020Article
- Biospecimens, Research Consent, and Distinguishing Cell Line Research.JAMA oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine-personalized response-exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.